Cybin is a biotech developing psychedelic-based drugs, like a psilocybin analog for depression and a DMT compound for anxiety, currently in clinical trials.
No revenue yet; the company burns cash, with net losses of USD 0.15B in fiscal 2026 and CAD 0.11B in 2025, funded by investors.
No approved products or revenue, so no durable edge. Competitors like Compass Pathways and MindMed are also racing in psychedelics, and Cybin's pipeline is early-stage and unproven.
